The estimated Net Worth of Subbarao V Uppaluri is at least 253 千$ dollars as of 16 June 2011. Subbarao Uppaluri owns over 1,000 units of Opko Health Inc stock worth over 252,720$ and over the last 17 years Subbarao sold OPK stock worth over 0$.
Subbarao has made over 7 trades of the Opko Health Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Subbarao bought 1,000 units of OPK stock worth 3,410$ on 16 June 2011.
The largest trade Subbarao's ever made was buying 200,000 units of Opko Health Inc stock on 13 July 2007 worth over 360,000$. On average, Subbarao trades about 21,299 units every 120 days since 2007. As of 16 June 2011 Subbarao still owns at least 162,000 units of Opko Health Inc stock.
You can see the complete history of Subbarao Uppaluri stock trades at the bottom of the page.
Subbarao's mailing address filed with the SEC is 4400 BISCAYNE BOULEVARD, 15TH FLOOR, , MIAMI, FL, 33137.
Over the last 17 years, insiders at Opko Health Inc have traded over 862,245$ worth of Opko Health Inc stock and bought 128,867,460 units worth 425,265,065$ . The most active insiders traders include Phillip Md Et Al Frost Neva...、Phillip Md Et Al Frost Gamm...、Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of 142,696$. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth 127,000$.
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
Opko Health Inc executives and other stock owners filed with the SEC include: